Your browser doesn't support javascript.
loading
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma.
Swan, Dawn; Gurney, Mark; Krawczyk, Janusz; Ryan, Aideen E; O'Dwyer, Michael.
Afiliación
  • Swan D; Department of Hematology, University Hospital Galway, Galway, Ireland.
  • Gurney M; School of Medicine, National University of Ireland Galway, Galway, Ireland.
  • Krawczyk J; Department of Hematology, University Hospital Galway, Galway, Ireland.
  • Ryan AE; School of Medicine, National University of Ireland Galway, Galway, Ireland.
  • O'Dwyer M; Department of Hematology, University Hospital Galway, Galway, Ireland.
Hemasphere ; 4(2): e350, 2020 Apr.
Article en En | MEDLINE | ID: mdl-32309787
The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hemasphere Año: 2020 Tipo del documento: Article País de afiliación: Irlanda Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hemasphere Año: 2020 Tipo del documento: Article País de afiliación: Irlanda Pais de publicación: Estados Unidos